Loading: 100%
American Renal Associates Holdings, Inc. logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees 4,601 (as per Q2 2017)no data available
Sector Medical Diagnostics & Research, HealthcareMedical Diagnostics & Research, Healthcareno data available
Ticker ARAno data available
Financial year endsFY ends End of Decemberno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 171014182226
datesClosing price (adj.)
13.10.201712.49
11.10.201713.65
04.10.201715.31
27.09.201714.58
20.09.201715.19
13.09.201714.84
06.09.201714.61
30.08.201713.67
23.08.201714.11
16.08.201715.05
09.08.201715.40
02.08.201716.34
26.07.201717.48
19.07.201718.01
12.07.201718.02
05.07.201718.49
27.06.201718.35
20.06.201718.56
13.06.201717.83
06.06.201716.28
30.05.201715.99
23.05.201717.11
16.05.201716.84
09.05.201716.64
02.05.201717.29
25.04.201717.98
18.04.201717.17
11.04.201717.43
04.04.201716.84
28.03.201716.02
21.03.201717.50
14.03.201717.67
07.03.201720.36
28.02.201722.60
21.02.201722.67
14.02.201721.92
07.02.201719.55
31.01.201719.22
24.01.201719.19
17.01.201720.44
10.01.201720.93
03.01.201721.92
27.12.201622.13
19.12.201622.26
12.12.201623.00
05.12.201624.30
28.11.201621.92
21.11.201622.01
14.11.201620.17
07.11.201618.55
31.10.201617.66
24.10.201618.59
17.10.201617.76
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
12.49n/a
Market Capitalisation
in million USD
391n/a
Enterprise Value
in million USD
0n/a
Common Shares Outstanding
as per Jun 30, 2017
31,283,812n/a
Preferred Shares Outstanding
as per Jun 30, 2017
n/a
Average Basic Shares Outstanding
TTM
30,937,084n/a
Average Diluted Shares Outstanding
TTM
30,794,158n/a
Index Membership
n/a
Business Summary
American Renal Associates Holdings Inc through its subsidiary is engaged in providing kidney dialysis services for patients suffering from chronic kidney failure, also known as end stage renal disease, or ESRD.
no data available
Key Financials & Ratios (all figures TTM as per , million USD, full statements further below)
Profit & Loss
Revenues 0n/a
Gross Profit 0n/a
Operating Income 0n/a
EBITDA 0n/a
Net Profit 0n/a
Balance Sheet
Cash and Cash Equivalents 0n/a
Receivables 0n/a
Total Current Assets 0n/a
PP&E 0n/a
Total Assets 0n/a
Accounts Payable 0n/a
Current Debt 0n/a
Total Current Liabilities 0n/a
Long-Term Debt 0n/a
Total Liabilities 0n/a
Total Equity 0n/a
Cash Flow
Depreciation & Amortisation 0n/a
Change in Working Capital 0n/a
Operating Cash Flow 0n/a
Net Change in PP&E and Intangibles 0n/a
Investing Cash Flow 0n/a
Dividends Paid 0n/a
Financing Cash Flow 0n/a
Total Change in Cash 0n/a
Free Cash Flow 0n/a
Profitability Ratios
Gross Margin 0.0%n/a
Operating Margin 0.0%n/a
Net Profit Margin 0.0%n/a
Return on Equity 0.0%n/a
Return on Assets 0.0%n/a
Per Share Figures
Basic EPS n/a
Diluted EPS n/a
Sales per Share n/a
Book Value per Share n/a
FCF per Share n/a
Dividends per Share n/a
Price Multiples
Price to Earnings Ratio n/a
Price to Sales Ratio n/a
Price to Book Value n/a
Price to Free Cash Flow n/a
Valuation Metrics
EV/EBITDA n/a
EV/Sales n/a
Book to Market Value n/a
Other Ratios
Current Ratio 0.0%n/a
Liabilities to Equity Ratio 0.0%n/a
Debt to Assets Ratio 0.0%n/a
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (9 items missing)
No data available for the selected time periods
in million USD FY '14FY '15FY '16
Patient service operating revenues
564
658
756
Provision for uncollectible accounts
-3
-5
-7
Net patient service operating revenues
561
653
750
Patient care costs
330
391
452
General and administrative
63
77
128
Transaction-related costs (Note 13)
29
32
34
Depreciation and amortization
0
2
2
Transaction-related costs (Note 3)
421
502
623
Total operating expenses
0
0
7
Certain legal matters (Note 20)
139
151
127
Operating Income
-44
-45
-36
Interest expense, net
0
0
-5
Loss on early extinguishment of debt
13
12
-1
Income tax expense
0
0
1
Income tax receivable agreement income
82
93
88
Net income
95
105
87
Income before income taxes
-66
-74
-89
Less: Net income attributable to noncontrolling interests
16
19
0
Remarks
restated on Mar 8, 2017 n/a
calculated values,
restated on Mar 8, 2017 n/a
calculated values,
restated on Mar 8, 2017 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (3 items missing)
No data available for the selected time periods
in million USD FY '14FY '15FY '16
Assets
Cash
n/a
91
101
Accounts receivable, less allowance for doubtful accounts
n/a
77
81
Inventories
n/a
4
5
Prepaid expenses and other current assets
n/a
19
18
Income tax receivable
n/a
3
5
Total current assets
n/a
194
210
Property and equipment, net of accumulated depreciation
n/a
143
170
Intangible assets, net of accumulated depreciation
n/a
26
26
Other long-term assets
n/a
7
7
Goodwill
n/a
569
573
Total assets
n/a
938
986
Liabilities and owners' equity
Accounts payable
n/a
23 22571000
31 31127000
Accrued compensation and benefits
n/a
23 22504000
29 29103000
Accrued expenses and other current liabilities
n/a
27 26788000
45 45286000
Current portion of long-term debt
n/a
26 25610000
48 48274000
Total current liabilities
n/a
97 97473000
154 153790000
Long-term debt, less current portion
n/a
657 657372000
522 522058000
Income tax receivable agreement payable
n/a
0 0
21 21200000
Other long-term liabilities
n/a
9 9483000
12 11670000
Deferred tax liabilities
n/a
15 15029000
1 1278000
Total liabilities
n/a
779 779357000
710 709996000
Commitments and contingencies (Note 12)
n/a
0 0
0 0
Noncontrolling interests subject to put provisions
n/a
108 108211000
130 130365000
Preferred stock
n/a
0 0
0 0
Common stock
n/a
0 98000
0 184000
Additional paid-in capital
n/a
0 0
95 95062000
Receivable from noncontrolling interests
n/a
-1 -529000
-1 -544000
Accumulated deficit
n/a
-128 -128261000
-129 -128646000
Accumulated other comprehensive loss, net of tax
n/a
-1 -501000
0 -100000
Total American Renal Associates Holdings, Inc. deficit
n/a
-129 -129193000
-34 -34044000
Noncontrolling interests not subject to put provisions
n/a
180 179903000
180 179707000
Total equity
n/a
51 50710000
146 145663000
Total liabilities and equity
n/a
938 938278000
986 986024000
Remarks restated on n/a restated on Mar 8, 2017 n/a restated on Aug 8, 2017 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (21 items missing)
No data available for the selected time periods
in million USD FY '14FY '15FY '16
Net income
82
93
88
Depreciation and amortization
29
32
34
Amortization of discounts, fees and deferred financing costs
3
3
3
Stock-based compensation
1
1
40
Noncash loss on early extinguishment of debt
0
0
5
Excess tax benefit for stock options exercised, net
10
5
-14
Premium paid for interest rate cap agreements
0
0
-1
Income tax receivable agreement income
0
0
0
Non-cash charge related to interest rate swap
0
-4
0
Payment related to tax receivable agreement
3
1
2
Non-cash rent charges
-2
-6
-4
Accounts receivable
0
0
1
Loss on disposal of assets
0
1
0
Inventories
-5
-1
-7
Prepaid expenses and other current assets
-1
-1
0
Other assets
-5
1
9
Accounts payable
1
4
7
Accrued compensation and benefits
3
5
11
Accrued expenses and other liabilities
118
134
172
Cash provided by operating activities
-40
-46
-61
Purchases of property, equipment and intangible assets
-5
-3
-5
Cash paid for acquisitions
-45
-49
-66
Cash used in investing activities
0
0
175
Proceeds from term loans
-21
-25
-275
Proceeds from issuance of common stock sold in initial public offering, net of underwriting discounts and offering expense
0
0
60
Payments on long-term debt
0
0
-1
Proceeds from issuance of long-term debt
0
0
0
Cash paid for debt issuance and other financing costs
0
4
0
Payments on capital lease obligations
0
0
-30
Excess tax benefit from stock option exercises
34
44
71
Dividends and dividend equivalents paid
0
0
0
Proceeds from term loans, net of deferred financing costs
0
-5
0
Proceeds from exercise of stock options
5
1
0
Payments of deferred offering costs
-68
-79
-94
Payments of deferred offering costs
0
0
0
Proceeds from issuance of common stock
1
2
0
Distributions to noncontrolling interests
6
7
7
Common stock repurchases for tax withholdings of net settlement equity awards
-1
-4
-8
Contributions from noncontrolling interests
0
0
23
Purchases of noncontrolling interests
-45
-55
-96
Tax Receivable Agreement
29
30
10
Remarks
restated on Mar 8, 2017 n/a
calculated values,
restated on Mar 8, 2017 n/a
calculated values,
restated on Mar 8, 2017 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo